Photo: Graeme Sloan/Bloomberg News AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients.

AstraZeneca’s chief executive said the U.K.’s “discouraging” tax rate was behind the company’s decision to build a $400 million API facility at the former Alexion campus in Dublin.

AstraZeneca unveiled plans for the Dublin facility in September 2021 with what was then a €337M price tag for construction of an API facility for small molecules.